Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Sportradar heads into its November 4 earnings with short sellers rebuilding positions and the lending market tightening sharply, even as the stock manages a modest weekly recovery.
The positioning story is the most interesting thing about SRAD right now. Short interest has climbed nearly 9% over the past week to around 16.3 million shares, continuing a trend that began in late September. The borrow cost has edged up to 1.03%, its highest reading in the 30-day window and up 13.5% on the week, a modest but directional move. More telling is what has happened to availability. Just a week ago, availability was above 78%. It has since tightened to 48%, roughly one share available for every two already borrowed. That shift points to a faster pace of new shorting than the lending pool can easily absorb, though at the 52-week trough the figure fell as low as 19%, so there is room to tighten further. Options, by contrast, offer little alarm: the put/call ratio is running at 0.30, slightly below its 20-day mean of 0.32 and well inside the past year's range. Call-side demand is not signalling a squeeze hunt, and the options market looks calm relative to what the lending data is saying.
The Street remains broadly positive but chastened. The post-August earnings reset left a clear mark: UBS cut to Neutral from Buy and slashed its target from $30 to $16, and most other firms lowered targets while keeping buy-equivalent ratings. Macquarie trimmed again this week, nudging its target to $19 from $20 while holding Outperform. The mean target across the coverage universe is around $16.17, implying roughly 33% upside from the current $12.18 close. The bull case rests on Sportradar's 2026 guidance of at least 21% constant-currency revenue growth and free cash flow conversion above 56%, plus the Kalshi prediction-market deal adding a new monetisation channel. Bears point to sports rights fee escalation, FX exposure, and the risk that programmatic advertising and incremental revenue streams disappoint, leaving EBITDA growth hostage to cost pressures the company cannot pass through. The ORTEX short score of 71.5 sits near the top of the past month's range and ranks in the seventh percentile of the universe, a bearish positioning signal that has been climbing consistently since late September.
The ownership picture adds some context. Spruce House Investment Management filed a fresh Schedule 13G in August disclosing a 5.8% stake, a new position. Canada Pension Plan holds 30.9% as last disclosed, and CEO Carsten Koerl holds roughly 27%. These are passive registrations under 13G, not activist positions, and stakes are as last disclosed around the 5% threshold. Separately, the ORTEX Alt Data layer shows retail attention on SRAD running at a z-score of 3.0 against the past 90 days of Wikipedia views and ORTEX page traffic, a notable spike in attention though the dataset has not been measured as a lead for the company's reported figures, so it is colour rather than a signal.
The last earnings reaction is worth keeping in mind. The August print prompted an 11.2% one-day drop and an 8.3% decline over the subsequent five days, the most punishing single-session response in the recent history data. The stock has since recovered some ground, up 5.4% on the week to $12.18, ahead of peers DKNG (up 0.8%) and GENI (up 0.8%), though FLUT also posted a solid week at 2.4%.
With 28 days to the next print, the question is whether the rebuilding short interest reflects renewed conviction around execution risk or is simply positioning for a repeat of August's volatility. The combination of tightening availability, a rising short score, and a still-sceptical UBS on the sidelines sets a clear bar for what November 4 needs to deliver.
See the live data behind this article on ORTEX.
Open SRAD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
